Literature DB >> 20596668

The prostate transglutaminase, TGase-4, coordinates with the HGFL/MSP-RON system in stimulating the migration of prostate cancer cells.

Wen G Jiang1, Lin Ye, Richard J Ablin, Howard G Kynaston, Malcolm D Mason.   

Abstract

The prostate transglutaminase, TGase-4, is a member of the transglutaminase family and is uniquely expressed in the prostate gland. The function of the protein is largely unknown, although an influence on cell motility and adhesion has been indicated. The present study investigated the impact of the differential expression of TGase-4 in human prostate cancer cells on RON, the hepatocyte growth factor-like/macrophage-stimulating protein (HGF-L/MSP) receptor, mediated cellular functions. Using human prostate cancer cell lines and prostate tissues, we demonstrated that human TGase-4 had a high degree of co-localisation with RON, primarily at the cell periphery and cell-cell adhesion region. High levels of TGase-4 expression in CAHPV10 cells and in PC3 cells engineered to over-express TGase-4 were associated with significantly increased cell motility in response to HGF-L, a clear contrast to wild-type and control cells. Neutralising antibody to RON and rhHGFL/MSP had no further bearing on the increased motility in TGase-4 over-expressing cells, although they had profound effect on the control cells. Akt pathway inhibitor significantly diminished the effect induced by HGF-L in the cells. Finally, over-expression of TGase-4 in prostate cancer cells resulted in autophosphorylation of RON. It is concluded that TGase-4 expression is intrinsically linked to the activation of RON in prostate cancer cells and that this autoactivation of RON contributes to the increased cell motility in TGase-4 expressing cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20596668     DOI: 10.3892/ijo_00000689

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes.

Authors:  Zhi Cao; Yang Wang; Zhi-Yong Liu; Zhen-Sheng Zhang; Shan-Cheng Ren; Yong-Wei Yu; Meng Qiao; Bei-Bei Zhai; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2013-08-26       Impact factor: 3.285

2.  Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer.

Authors:  Nicholas E Brown; Camille Sullivan; Susan E Waltz
Journal:  EMS Cancer Sci J       Date:  2018-07-30

3.  Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7/IL-24 in prostate cancer.

Authors:  Richard J Ablin; Howard G Kynaston; Malcolm D Mason; Wen G Jiang
Journal:  J Transl Med       Date:  2011-04-28       Impact factor: 5.531

4.  Stage-specific analysis of plasma protein profiles in ovarian cancer: Difference in-gel electrophoresis analysis of pooled clinical samples.

Authors:  Mark J Bailey; Kristy L Shield-Artin; Karen Oliva; Mustafa Ayhan; Simone Reisman; Gregory E Rice
Journal:  J Carcinog       Date:  2013-06-29

5.  Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain.

Authors:  Wen G Jiang; Lin Ye; Andrew J Sanders; Fiona Ruge; Howard G Kynaston; Richard J Ablin; Malcolm D Mason
Journal:  J Transl Med       Date:  2013-10-25       Impact factor: 5.531

6.  Urinary proteomic analysis during pregnancy and its potential application in early prediction of gestational diabetes mellitus and spontaneous abortion.

Authors:  Xiangqing Wang; Mindi Zhao; Zhengguang Guo; Shuoning Song; Shixuan Liu; Tao Yuan; Yong Fu; Yingyue Dong; Haidan Sun; Xiaoyan Liu; Dongdong Zhou; Weigang Zhao; Wei Sun
Journal:  Ann Transl Med       Date:  2022-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.